Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Two Doses of Parenteral Amoxicillin Plus Single Dose Gentamicin Compared to Four Doses of Parenteral Ampicillin Plus Single Dose Gentamicin in Managing Children Hospitalized With WHO Classified Severe Pneumonia: a RCT
Brief Summary: Burden: Pneumonia remains the leading infectious cause of death accounting for 920,000 children under five around the world. This means a loss of over 2,500 child lives every day, or over 100 every hour. Since 2000, the number of child deaths caused by pneumonia has decreased by 47 percent. The tremendous progress made is due in part to the rapid roll-out of vaccines, better nutrition, and improved care-seeking and treatment for symptoms. However, pneumonia hasn't declined as quickly as other diseases such as malaria (58%), HIV/AIDS (61%), and measles (85%).

Knowledge gap: The Lancet Series on Childhood Pneumonia and Diarrhea has reported that case management is one of the three most effective interventions to reduce pneumonia deaths in children. It is also noted that the cost-effectiveness of these interventions in the national health system needs urgent assessment. It was suggested to find out means to reduce hospital stay without compromising the quality of care.

Relevance: The main purpose of the study is to compare the efficacy of two doses of parenteral Amoxicillin plus single-dose Gentamicin compared to four doses of parenteral Ampicillin plus single-dose Gentamicin. After 72 hours of treatment injectable Amoxicillin or injection Ampicillin will be switched to or replaced by oral Amoxicillin and will be discharged with an advice to attend to Ambulatory Care Unit (ACU) to receive a once-daily dose of injection Gentamicin for a total of 5 days. It is anticipated that this modified therapy will reduce the hospitalization stay of children with severe pneumonia and would therefore be relevant in countries with the resource-poor settings. By reducing the hospitalization period, this therapy has the potentials to reduce hospital-acquired infection.

Hypothesis (if any): Rate of treatment failure with two doses of injectable Amoxicillin plus single-dose Gentamicin will be no more than that of four doses of injectable Ampicillin plus single-dose Gentamicin in the management of children between 2 months to 59 months hospitalized for WHO classified severe pneumonia.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
D: Arm Label: Ampicillin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin | Arm Label: Amoxicillin arm; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin arm, Ampicillin arm

Answer: D